No other colon cancer multi-gene test is backed by as much data as the Oncotype DX Colon Recurrence Score test. It’s the first and only genomic test for colon cancer with Level 1 evidence.1-4
The Colon Recurrence Score test vs. traditional assessment methods
Go beyond traditional measurements to predict each patient’s individualized risk of recurrence.
Traditional clinical and pathologic factors provide some prognostic insight, but they can’t quantify individual risk of recurrence for patients with colon cancer. As a result, helping your patient make appropriate treatment decisions with clinical and pathologic factors alone can be difficult.
Only the Colon Recurrence Score test offers a precise and more accurate estimate of recurrence risk, helping you determine adjuvant treatment for your patient with anatomic stages II, MMR-P or III A/B colon cancers.1-4
The Colon Recurrence Score test goes beyond traditional measurements (nodal assessment, bowel perforation or obstruction, tumor grade, lymphatic or venous invasion, T-stage and MMR status) to predict each patient’s individualized risk of recurrence. It does so by looking at the unique biology of the tumor sample removed during their surgery.
Unlike pathologic and clinical methods, the Colon Recurrence Score result1-4:
- Reflects the individual biology of each patient’s tumor, offering a more complete picture of your patient’s unique risk.
- Quantifies risk of recurrence for anatomic stage II, MMR-P patients and stage III A/B patients.
- Highlights the importance of biologic information (i.e., MMR and Recurrence Score result).
In addition, the Colon Recurrence Score report enhances the patient conversation when discussing risk and treatment options. Learn more about the Recurrence Score results.
Practical, actionable insights for anatomic stage II, MMR-P and stage III A/B patients
A HIGH Recurrence Score result
can identify anatomic stage II, MMR-P patients who have a higher risk of recurrence.1-4
These patients can expect a greater absolute benefit from chemotherapy after their surgery.
A LOW Recurrence Score result
can identify anatomic stage III A/B patients who have lower-than-average risk of recurrence.3,4
These patients can expect a lower absolute benefit from the addition of oxaliplatin to 5-FU/LV.
The benefits of genomic testing
The Colon Recurrence Score test examines the activity of 12 genes in a patient’s tumor. The Colon Recurrence Score test looks at the activity of these genes to help you and your patient make decisions about treatment.
Find out if your patient is eligible or order the test.